SECAUCUS, N.J., July 23,
2020 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:
DGX), the world's leading provider of diagnostic information
services, announced today financial results for the second quarter
ended June 30, 2020, which are consistent with the preliminary
results reported on July 13,
2020.
"In one of the most challenging periods in our history, Quest
Diagnostics stepped up and rapidly expanded COVID-19 testing for
the country and delivered stronger-than-expected performance in the
second quarter," said Steve
Rusckowski, Chairman, CEO and President, Quest Diagnostics.
"Our base testing volume declined versus 2019 because of the
pandemic and was partially offset by COVID-19 testing. I am proud
of Quest's employees who have been on the frontlines of healthcare,
answering the call in fighting the COVID-19 pandemic."
Mr. Rusckowski concluded: "Looking forward to the rest of the
year, we will continue to expand COVID-19 testing capacity while
also continuing to serve our customers as they continue to recover
from the pandemic. We have re-established our financial outlook for
the remainder of the year with a broad range that reflects
uncertainty caused by the pandemic."
|
Three Months Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
|
2020
|
|
2019
|
|
Change
|
|
2020
|
|
2019
|
|
Change
|
|
|
(dollars in millions,
except per share data)
|
|
Reported:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
revenues
|
$
|
1,827
|
|
|
$
|
1,953
|
|
|
(6.4)
|
%
|
|
$
|
3,649
|
|
|
$
|
3,844
|
|
|
(5.1)
|
%
|
|
Diagnostic Information
Services revenues
|
$
|
1,764
|
|
|
$
|
1,872
|
|
|
(5.7)
|
%
|
|
$
|
3,508
|
|
|
$
|
3,684
|
|
|
(4.8)
|
%
|
|
Revenue per
requisition
|
|
|
|
|
15.3
|
%
|
|
|
|
|
|
6.4
|
%
|
|
Requisition
volume
|
|
|
|
|
(17.7)
|
%
|
|
|
|
|
|
(10.2)
|
%
|
|
Organic
requisition volume
|
|
|
|
|
(18.2)
|
%
|
|
|
|
|
|
(10.5)
|
%
|
|
Operating income
(a)
|
$
|
283
|
|
|
$
|
307
|
|
|
(7.6)
|
%
|
|
$
|
458
|
|
|
$
|
555
|
|
|
(17.5)
|
%
|
|
Operating income as a
percentage of net revenues (a)
|
15.5
|
%
|
|
15.7
|
%
|
|
(0.2)
|
%
|
|
12.5
|
%
|
|
14.4
|
%
|
|
(1.9)
|
%
|
|
Income from
continuing operations attributable to Quest Diagnostics
(a)
|
$
|
185
|
|
|
$
|
206
|
|
|
(10.1)
|
%
|
|
$
|
284
|
|
|
$
|
370
|
|
|
(23.3)
|
%
|
|
Diluted EPS
(a)
|
$
|
1.36
|
|
|
$
|
1.51
|
|
|
(9.7)
|
%
|
|
$
|
2.09
|
|
|
$
|
2.71
|
|
|
(23.0)
|
%
|
|
Cash provided by
operations
|
$
|
355
|
|
|
$
|
321
|
|
|
10.4
|
%
|
|
$
|
602
|
|
|
$
|
596
|
|
|
0.9
|
%
|
|
Capital
expenditures
|
$
|
82
|
|
|
$
|
85
|
|
|
(4.0)
|
%
|
|
$
|
165
|
|
|
$
|
132
|
|
|
24.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted:
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
income
|
$
|
294
|
|
|
$
|
352
|
|
|
(16.2)
|
%
|
|
$
|
519
|
|
|
$
|
638
|
|
|
(18.7)
|
%
|
|
Operating income as a
percentage of net revenues
|
16.1
|
%
|
|
18.0
|
%
|
|
(1.9)
|
%
|
|
14.2
|
%
|
|
16.6
|
%
|
|
(2.4)
|
%
|
|
Income from
continuing operations attributable to Quest Diagnostics
|
$
|
193
|
|
|
$
|
237
|
|
|
(18.3)
|
%
|
|
$
|
321
|
|
|
$
|
427
|
|
|
(24.7)
|
%
|
|
Diluted
EPS
|
$
|
1.42
|
|
|
$
|
1.73
|
|
|
(17.9)
|
%
|
|
$
|
2.36
|
|
|
$
|
3.13
|
|
|
(24.3)
|
%
|
|
|
|
(a)
|
For further details
impacting the year-over-year comparisons related to operating
income, operating income as a percentage of net revenues, income
from continuing operations attributable to Quest Diagnostics, and
diluted EPS, see note 2 of the financial tables attached
below.
|
Outlook Reinstated for full year 2020
The company reinstated its financial outlook for full year 2020
after withdrawing it in April 2020. Current estimates for
full year 2020 results are as follows:
|
Low
|
|
High
|
Net
revenues
|
$8.0
billion
|
|
$8.6
billion
|
Net revenues
increase
|
3.5%
|
|
11.3%
|
Reported diluted
EPS
|
$5.66
|
|
$7.66
|
Adjusted diluted
EPS
|
$6.60
|
|
$8.60
|
Cash provided by
operations
|
At least $1.25
billion
|
Capital
expenditures
|
$375
million
|
|
$400
million
|
Outlook ranges for full year 2020 reflect a number of
assumptions that are subject to change based on uncertainties
related to the impact of the COVID-19 pandemic. The company
intends to provide further detail regarding these assumptions on
its quarterly conference call today.
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to
measures under accounting principles generally accepted in
the United States ("GAAP"). The
term "adjusted" refers to non-GAAP operating performance measures
that exclude special items such as restructuring and integration
charges, certain financial impacts resulting from the COVID-19
pandemic, amortization expense, excess tax benefits ("ETB")
associated with stock-based compensation, and other items.
Non-GAAP adjusted measures are presented because management
believes those measures are useful adjuncts to GAAP results.
Non-GAAP adjusted measures should not be considered as an
alternative to the corresponding measures determined under GAAP.
Management may use these non-GAAP measures to evaluate our
performance period over period and relative to competitors, to
analyze the underlying trends in our business, to establish
operational budgets and forecasts and for incentive compensation
purposes. We believe that these non-GAAP measures are useful to
investors and analysts to evaluate our performance period over
period and relative to competitors, as well as to analyze the
underlying trends in our business and to assess our performance.
The additional tables attached below include reconciliations of
non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to
discuss financial results beginning at 8:30
a.m. Eastern Time today. The conference call can be
accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally,
passcode: 7895081; or via live webcast on the company's website at
www.QuestDiagnostics.com/investor. The company suggests
participants dial in approximately 10 minutes before the call.
A replay of the call may be accessed online at
www.QuestDiagnostics.com/investor or by phone at 888-566-0435
for domestic callers or 402-998-0605 for international callers. No
passcode is required. Telephone replays will be available
from approximately 10:30 a.m. Eastern
Time on July 23, 2020 until
midnight Eastern Time on August 6, 2020. Anyone listening to the
call is encouraged to read the company's periodic reports, on file
with the Securities and Exchange Commission, including the
discussion of risk factors and historical results of operations and
financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve
health outcomes. Derived from the world's largest database of
clinical lab results, our diagnostic insights reveal new avenues to
identify and treat disease, inspire healthy behaviors and improve
health care management. Quest annually serves one in three
adult Americans and half the physicians and hospitals in
the United States, and our 47,000
employees understand that, in the right hands and with the right
context, our diagnostic insights can inspire actions that transform
lives. www.QuestDiagnostics.com.
The statements in this press release which are not historical
facts may be forward-looking statements. Readers are
cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date that they are made and
which reflect management's current estimates, projections,
expectations or beliefs and which involve risks and uncertainties
that could cause actual results and outcomes to be materially
different. Risks and uncertainties that may affect the future
results of the company include, but are not limited to, impacts of
the COVID-19 pandemic and measures taken in response, adverse
results from pending or future government investigations, lawsuits
or private actions, the competitive environment, the complexity of
billing, reimbursement and revenue recognition for clinical
laboratory testing, changes in government regulations, changing
relationships with customers, payers, suppliers or strategic
partners and other factors discussed in the company's most recently
filed Annual Report on Form 10-K and in any of the company's
subsequently filed Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K, including those discussed in the "Business,"
"Risk Factors," "Cautionary Factors that May Affect Future Results"
and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables,
is available online in the Newsroom section at
www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
Quest Diagnostics
Incorporated and Subsidiaries
Consolidated
Statements of Operations
For the Three and
Six Months Ended June 30, 2020 and 2019
(in millions,
except per share data)
(unaudited)
|
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
Net
revenues
|
$
|
1,827
|
|
|
$
|
1,953
|
|
|
$
|
3,649
|
|
|
$
|
3,844
|
|
|
|
|
|
|
|
|
|
Operating costs
and expenses and other operating income:
|
|
|
|
|
|
|
|
Cost of
services
|
1,221
|
|
|
1,265
|
|
|
2,491
|
|
|
2,509
|
|
Selling, general and
administrative
|
360
|
|
|
362
|
|
|
707
|
|
|
746
|
|
Amortization of
intangible assets
|
25
|
|
|
25
|
|
|
50
|
|
|
49
|
|
Other operating
income, net
|
(62)
|
|
|
(6)
|
|
|
(57)
|
|
|
(15)
|
|
Total operating costs
and expenses, net
|
1,544
|
|
|
1,646
|
|
|
3,191
|
|
|
3,289
|
|
|
|
|
|
|
|
|
|
Operating
income
|
283
|
|
|
307
|
|
|
458
|
|
|
555
|
|
|
|
|
|
|
|
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
Interest expense,
net
|
(41)
|
|
|
(45)
|
|
|
(82)
|
|
|
(89)
|
|
Other income
(expense), net
|
13
|
|
|
3
|
|
|
(3)
|
|
|
12
|
|
Total non-operating
expenses, net
|
(28)
|
|
|
(42)
|
|
|
(85)
|
|
|
(77)
|
|
|
|
|
|
|
|
|
|
Income from
continuing operations before income taxes and equity in earnings of
equity method investees
|
255
|
|
|
265
|
|
|
373
|
|
|
478
|
|
Income tax
expense
|
(66)
|
|
|
(63)
|
|
|
(92)
|
|
|
(113)
|
|
Equity in earnings
of equity method investees, net of taxes
|
4
|
|
|
17
|
|
|
18
|
|
|
30
|
|
Income from
continuing operations
|
193
|
|
|
219
|
|
|
299
|
|
|
395
|
|
Income from
discontinued operations, net of taxes
|
—
|
|
|
20
|
|
|
—
|
|
|
20
|
|
Net
income
|
193
|
|
|
239
|
|
|
299
|
|
|
415
|
|
Less: Net income
attributable to noncontrolling interests
|
8
|
|
|
13
|
|
|
15
|
|
|
25
|
|
Net income
attributable to Quest Diagnostics
|
$
|
185
|
|
|
$
|
226
|
|
|
$
|
284
|
|
|
$
|
390
|
|
|
|
|
|
|
|
|
|
Amounts
attributable to Quest Diagnostics' common
stockholders:
|
|
|
|
|
|
|
|
Income from
continuing operations
|
$
|
185
|
|
|
$
|
206
|
|
|
$
|
284
|
|
|
$
|
370
|
|
Income from
discontinued operations, net of taxes
|
—
|
|
|
20
|
|
|
—
|
|
|
20
|
|
Net income
|
$
|
185
|
|
|
$
|
226
|
|
|
$
|
284
|
|
|
$
|
390
|
|
|
|
|
|
|
|
|
|
Earnings per share
attributable to Quest Diagnostics' common stockholders -
basic:
|
|
|
|
|
|
|
|
Income from
continuing operations
|
$
|
1.38
|
|
|
$
|
1.52
|
|
|
$
|
2.12
|
|
|
$
|
2.74
|
|
Income from
discontinued operations
|
—
|
|
|
0.15
|
|
|
—
|
|
|
0.15
|
|
Net income
|
$
|
1.38
|
|
|
$
|
1.67
|
|
|
$
|
2.12
|
|
|
$
|
2.89
|
|
|
|
|
|
|
|
|
|
Earnings per share
attributable to Quest Diagnostics' common stockholders -
diluted:
|
|
|
|
|
|
|
|
Income from
continuing operations
|
$
|
1.36
|
|
|
$
|
1.51
|
|
|
$
|
2.09
|
|
|
$
|
2.71
|
|
Income from
discontinued operations
|
—
|
|
|
0.15
|
|
|
—
|
|
|
0.15
|
|
Net income
|
$
|
1.36
|
|
|
$
|
1.66
|
|
|
$
|
2.09
|
|
|
$
|
2.86
|
|
|
|
|
|
|
|
|
|
Weighted average
common shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
134
|
|
|
135
|
|
|
134
|
|
|
134
|
|
|
|
|
|
|
|
|
|
Diluted
|
136
|
|
|
136
|
|
|
135
|
|
|
136
|
|
Quest Diagnostics
Incorporated and Subsidiaries
Consolidated
Balance Sheets
June 30, 2020
and December 31, 2019
(in millions,
except per share data)
(unaudited)
|
|
|
June 30,
2020
|
|
December
31,
2019
|
Assets
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
|
988
|
|
|
$
|
1,192
|
|
Accounts receivable,
net
|
1,126
|
|
|
1,063
|
|
Inventories
|
154
|
|
|
123
|
|
Prepaid expenses and
other current assets
|
112
|
|
|
112
|
|
Total current
assets
|
2,380
|
|
|
2,490
|
|
Property, plant
and equipment, net
|
1,505
|
|
|
1,453
|
|
Operating lease
right-of-use assets
|
522
|
|
|
518
|
|
Goodwill
|
6,789
|
|
|
6,619
|
|
Intangible assets,
net
|
1,141
|
|
|
1,121
|
|
Investments in
equity method investees
|
495
|
|
|
482
|
|
Other
assets
|
158
|
|
|
160
|
|
Total
assets
|
$
|
12,990
|
|
|
$
|
12,843
|
|
|
|
|
|
Liabilities and
Stockholders' Equity
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts payable and
accrued expenses
|
$
|
1,142
|
|
|
$
|
1,041
|
|
Current portion of
long-term debt
|
555
|
|
|
804
|
|
Current portion of
long-term operating lease liabilities
|
146
|
|
|
145
|
|
Total current
liabilities
|
1,843
|
|
|
1,990
|
|
Long-term
debt
|
4,020
|
|
|
3,966
|
|
Long-term
operating lease liabilities
|
416
|
|
|
413
|
|
Other
liabilities
|
753
|
|
|
711
|
|
Redeemable
noncontrolling interest
|
77
|
|
|
76
|
|
Stockholders'
equity:
|
|
|
|
Quest Diagnostics
stockholders' equity:
|
|
|
|
Common stock, par
value $0.01 per share; 600 shares authorized as of both June 30,
2020 and December 31, 2019; 217 shares issued as of both June 30,
2020 and December 31, 2019
|
2
|
|
|
2
|
|
Additional paid-in
capital
|
2,764
|
|
|
2,722
|
|
Retained
earnings
|
8,307
|
|
|
8,174
|
|
Accumulated other
comprehensive loss
|
(55)
|
|
|
(39)
|
|
Treasury
stock, at cost; 83 and 84 shares as of June 30, 2020 and December
31, 2019, respectively
|
(5,187)
|
|
|
(5,218)
|
|
Total Quest
Diagnostics stockholders' equity
|
5,831
|
|
|
5,641
|
|
Noncontrolling
interests
|
50
|
|
|
46
|
|
Total stockholders'
equity
|
5,881
|
|
|
5,687
|
|
Total liabilities
and stockholders' equity
|
$
|
12,990
|
|
|
$
|
12,843
|
|
Quest Diagnostics
Incorporated and Subsidiaries
Consolidated
Statements of Cash Flows
For the Six Months
Ended June 30, 2020 and 2019
(in
millions)
(unaudited)
|
|
|
Six Months Ended
June 30,
|
|
2020
|
|
2019
|
Cash flows from
operating activities:
|
|
|
|
Net income
|
$
|
299
|
|
|
$
|
415
|
|
Adjustments to
reconcile net income to net cash provided by operating
activities:
|
|
|
|
Depreciation and
amortization
|
174
|
|
|
165
|
|
Provision for credit
losses
|
13
|
|
|
5
|
|
Deferred income tax
provision
|
23
|
|
|
13
|
|
Stock-based
compensation expense
|
31
|
|
|
32
|
|
Other, net
|
3
|
|
|
(33)
|
|
Changes in operating
assets and liabilities:
|
|
|
|
Accounts
receivable
|
(75)
|
|
|
(81)
|
|
Accounts payable and
accrued expenses
|
42
|
|
|
27
|
|
Income taxes
payable
|
51
|
|
|
15
|
|
Termination of
interest rate swap agreements
|
40
|
|
|
—
|
|
Other assets and
liabilities, net
|
1
|
|
|
38
|
|
Net cash provided
by operating activities
|
602
|
|
|
596
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
Business
acquisitions, net of cash acquired
|
(228)
|
|
|
(56)
|
|
Capital
expenditures
|
(165)
|
|
|
(132)
|
|
Increase in
investments and other assets
|
(18)
|
|
|
(14)
|
|
Net cash used in
investing activities
|
(411)
|
|
|
(202)
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
Proceeds from
borrowings
|
749
|
|
|
1,484
|
|
Repayments of
debt
|
(1,001)
|
|
|
(1,448)
|
|
Purchases of treasury
stock
|
(75)
|
|
|
(103)
|
|
Exercise of stock
options
|
117
|
|
|
66
|
|
Employee payroll tax
withholdings on stock issued under stock-based compensation
plans
|
(13)
|
|
|
(16)
|
|
Dividends
paid
|
(146)
|
|
|
(143)
|
|
Distributions to
noncontrolling interest partners
|
(10)
|
|
|
(27)
|
|
Other financing
activities, net
|
(16)
|
|
|
(69)
|
|
Net cash used in
financing activities
|
(395)
|
|
|
(256)
|
|
|
|
|
|
Net change in cash
and cash equivalents and restricted cash
|
(204)
|
|
|
138
|
|
Cash and cash
equivalents and restricted cash, beginning of period
|
1,192
|
|
|
135
|
|
Cash and cash
equivalents and restricted cash, end of period
|
$
|
988
|
|
|
$
|
273
|
|
|
|
|
|
Cash paid during
the period for:
|
|
|
|
Interest
|
$
|
103
|
|
|
$
|
91
|
|
Income
taxes
|
$
|
20
|
|
|
$
|
83
|
|
Notes to Financial Tables
1)
|
The
computation of basic and diluted earnings per common share is as
follows:
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
(in millions, except
per share data)
|
Amounts
attributable to Quest Diagnostics' common
stockholders:
|
|
|
|
|
|
|
|
Income from
continuing operations
|
$
|
185
|
|
|
$
|
206
|
|
|
$
|
284
|
|
|
$
|
370
|
|
Income from
discontinued operations, net of taxes
|
—
|
|
|
20
|
|
|
—
|
|
|
20
|
|
Net income
attributable to Quest Diagnostics' common stockholders
|
$
|
185
|
|
|
$
|
226
|
|
|
$
|
284
|
|
|
$
|
390
|
|
|
|
|
|
|
|
|
|
Income from
continuing operations
|
$
|
185
|
|
|
$
|
206
|
|
|
$
|
284
|
|
|
$
|
370
|
|
Less: earnings
allocated to participating securities
|
1
|
|
|
—
|
|
|
1
|
|
|
1
|
|
Earnings available to
Quest Diagnostics' common stockholders - basic and
diluted
|
$
|
184
|
|
|
$
|
206
|
|
|
$
|
283
|
|
|
$
|
369
|
|
|
|
|
|
|
|
|
|
Weighted average
common shares outstanding - basic
|
134
|
|
|
135
|
|
|
134
|
|
|
134
|
|
Effect of dilutive
securities:
|
|
|
|
|
|
|
|
Stock options and
performance share units
|
2
|
|
|
1
|
|
|
1
|
|
|
2
|
|
Weighted average
common shares outstanding - diluted
|
136
|
|
|
136
|
|
|
135
|
|
|
136
|
|
|
|
|
|
|
|
|
|
Earnings per share
attributable to Quest Diagnostics' common stockholders -
basic:
|
|
|
|
|
|
|
|
Income from
continuing operations
|
$
|
1.38
|
|
|
$
|
1.52
|
|
|
$
|
2.12
|
|
|
$
|
2.74
|
|
Income from
discontinued operations
|
—
|
|
|
0.15
|
|
|
—
|
|
|
0.15
|
|
Net income
|
$
|
1.38
|
|
|
$
|
1.67
|
|
|
$
|
2.12
|
|
|
$
|
2.89
|
|
|
|
|
|
|
|
|
|
Earnings per share
attributable to Quest Diagnostics' common stockholders -
diluted:
|
|
|
|
|
|
|
|
Income from
continuing operations
|
$
|
1.36
|
|
|
$
|
1.51
|
|
|
$
|
2.09
|
|
|
$
|
2.71
|
|
Income from
discontinued operations
|
—
|
|
|
0.15
|
|
|
—
|
|
|
0.15
|
|
Net income
|
$
|
1.36
|
|
|
$
|
1.66
|
|
|
$
|
2.09
|
|
|
$
|
2.86
|
|
2)
|
The following tables
reconcile reported GAAP results to non-GAAP adjusted
results:
|
|
Three Months Ended
June 30, 2020
|
|
|
(dollars in
millions, except per share data)
|
|
|
Operating
income
|
|
Operating
income as a
percentage of
net revenues
|
|
Income tax
expense (d)
|
|
Equity in
earnings of
equity method
investees, net
of taxes
|
|
Income from
continuing
operations
attributable to
Quest
Diagnostics
|
|
Diluted
EPS
|
|
As
reported
|
$
|
283
|
|
|
15.5
|
%
|
|
$
|
(66)
|
|
|
$
|
4
|
|
|
$
|
185
|
|
|
$
|
1.36
|
|
|
Restructuring and
integration charges (a)
|
9
|
|
|
0.6
|
|
|
(1)
|
|
|
—
|
|
|
8
|
|
|
0.06
|
|
|
COVID-19 impact
(b)
|
(23)
|
|
|
(1.3)
|
|
|
10
|
|
|
(3)
|
|
|
(17)
|
|
|
(0.13)
|
|
|
Amortization
expense
|
25
|
|
|
1.3
|
|
|
(7)
|
|
|
3
|
|
|
21
|
|
|
0.16
|
|
|
ETB
|
—
|
|
|
—
|
|
|
(4)
|
|
|
—
|
|
|
(4)
|
|
|
(0.03)
|
|
|
As
adjusted
|
$
|
294
|
|
|
16.1
|
%
|
|
$
|
(68)
|
|
|
$
|
4
|
|
|
$
|
193
|
|
|
$
|
1.42
|
|
|
|
|
|
Six Months Ended
June 30, 2020
|
|
(dollars in
millions, except per share data)
|
|
Operating
income
|
|
Operating
income as a
percentage of
net revenues
|
|
Income tax
expense (d)
|
|
Equity in
earnings of
equity method
investees, net
of taxes
|
|
Income from
continuing
operations
attributable to
Quest
Diagnostics
|
|
Diluted
EPS
|
As
reported
|
$
|
458
|
|
|
12.5
|
%
|
|
$
|
(92)
|
|
|
$
|
18
|
|
|
$
|
284
|
|
|
$
|
2.09
|
|
Restructuring and
integration charges (a)
|
25
|
|
|
0.7
|
|
|
(5)
|
|
|
—
|
|
|
20
|
|
|
0.15
|
|
COVID-19 impact
(b)
|
(14)
|
|
|
(0.4)
|
|
|
7
|
|
|
(3)
|
|
|
(13)
|
|
|
(0.10)
|
|
Amortization
expense
|
50
|
|
|
1.4
|
|
|
(14)
|
|
|
6
|
|
|
42
|
|
|
0.31
|
|
ETB
|
—
|
|
|
—
|
|
|
(12)
|
|
|
—
|
|
|
(12)
|
|
|
(0.09)
|
|
As
adjusted
|
$
|
519
|
|
|
14.2
|
%
|
|
$
|
(116)
|
|
|
$
|
21
|
|
|
$
|
321
|
|
|
$
|
2.36
|
|
|
|
|
Three Months Ended
June 30, 2019
|
|
(dollars in
millions, except per share data)
|
|
Operating
income
|
|
Operating
income as a
percentage of
net revenues
|
|
Income tax
expense (d)
|
|
Equity in
earnings of
equity method
investees, net
of taxes
|
|
Income from
continuing
operations
attributable to
Quest
Diagnostics
|
|
Diluted
EPS
|
As
reported
|
$
|
307
|
|
|
15.7
|
%
|
|
$
|
(63)
|
|
|
$
|
17
|
|
|
$
|
206
|
|
|
$
|
1.51
|
|
Restructuring and
integration charges (a)
|
26
|
|
|
1.3
|
|
|
(7)
|
|
|
—
|
|
|
19
|
|
|
0.14
|
|
Other (c)
|
(6)
|
|
|
(0.3)
|
|
|
—
|
|
|
—
|
|
|
(6)
|
|
|
(0.04)
|
|
Amortization
expense
|
25
|
|
|
1.3
|
|
|
(7)
|
|
|
5
|
|
|
23
|
|
|
0.16
|
|
ETB
|
—
|
|
|
—
|
|
|
(5)
|
|
|
—
|
|
|
(5)
|
|
|
(0.04)
|
|
As
adjusted
|
$
|
352
|
|
|
18.0
|
%
|
|
$
|
(82)
|
|
|
$
|
22
|
|
|
$
|
237
|
|
|
$
|
1.73
|
|
|
|
|
Six Months Ended
June 30, 2019
|
|
(dollars in
millions, except per share data)
|
|
Operating
income
|
|
Operating
income as a
percentage of
net revenues
|
|
Income tax
expense (d)
|
|
Equity in
earnings of
equity method
investees, net of
taxes
|
|
Income from
continuing
operations
attributable to
Quest
Diagnostics
|
|
Diluted
EPS
|
As
reported
|
$
|
555
|
|
|
14.4
|
%
|
|
$
|
(113)
|
|
|
$
|
30
|
|
|
$
|
370
|
|
|
$
|
2.71
|
|
Restructuring and
integration charges (a)
|
48
|
|
|
1.3
|
|
|
(13)
|
|
|
—
|
|
|
35
|
|
|
0.26
|
|
Other (c)
|
(14)
|
|
|
(0.4)
|
|
|
(1)
|
|
|
—
|
|
|
(15)
|
|
|
(0.10)
|
|
Amortization
expense
|
49
|
|
|
1.3
|
|
|
(14)
|
|
|
10
|
|
|
45
|
|
|
0.32
|
|
ETB
|
—
|
|
|
—
|
|
|
(8)
|
|
|
—
|
|
|
(8)
|
|
|
(0.06)
|
|
As
adjusted
|
$
|
638
|
|
|
16.6
|
%
|
|
$
|
(149)
|
|
|
$
|
40
|
|
|
$
|
427
|
|
|
$
|
3.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
For both the three
and six months ended June 30, 2020 and 2019, represents costs
primarily associated with systems conversions and integration
incurred in connection with further restructuring and integrating
our business. The following table summarizes the pre-tax
impact of restructuring and integration charges on the company's
consolidated statements of operations:
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
|
|
(dollars in
millions)
|
|
|
Cost of
services
|
$
|
3
|
|
|
$
|
11
|
|
|
$
|
10
|
|
|
$
|
22
|
|
|
|
Selling, general and
administrative
|
6
|
|
|
15
|
|
|
15
|
|
|
26
|
|
|
|
Operating
income
|
$
|
9
|
|
|
$
|
26
|
|
|
$
|
25
|
|
|
$
|
48
|
|
|
(b)
|
For both the three
and six months ended June 30, 2020, represents the impact of
certain items resulting from the COVID-19 pandemic including $65
million of income recognized attributable to the receipt of the
initial tranche of funds from the government that were appropriated
to healthcare providers under the Coronavirus Aid, Relief, and
Economic Security Act ("CARES Act"), partially offset by expense
associated with a one-time payment to eligible employees to help
offset expenses they incurred as a result of COVID-19, certain
asset impairment charges, and incremental costs incurred primarily
to protect the health and safety of the company's employees and
customers.
|
|
|
The following table
summarizes the pre-tax impact of these COVID-19 items on the
company's consolidated statements of operations:
|
|
|
|
|
|
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
|
|
(dollars in
millions)
|
|
|
Cost of
services
|
$
|
34
|
|
|
$
|
—
|
|
|
$
|
35
|
|
|
$
|
—
|
|
|
|
Selling, general and
administrative
|
5
|
|
|
—
|
|
|
8
|
|
|
—
|
|
|
|
Other operating
income, net
|
(62)
|
|
|
—
|
|
|
(57)
|
|
|
—
|
|
|
|
Operating
income
|
$
|
(23)
|
|
|
$
|
—
|
|
|
$
|
(14)
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
attributable to noncontrolling interest
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
3
|
|
|
$
|
—
|
|
|
(c)
|
For the
three months ended June 30, 2019, the pre-tax impact
primarily represents a gain associated with the decrease in the
fair value of the contingent consideration accrual associated with
a previous acquisition. For the six months ended
June 30, 2019, the pre-tax impact primarily represents a gain
associated with an insurance claim for hurricane related losses,
and a gain associated with the decrease in the fair value of the
contingent consideration accrual associated with a previous
acquisition, partially offset by non-cash asset impairment
charges. The following table summarizes the pre-tax impact of
these other items on the company's consolidated statements of
operations:
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months
Ended
June 30,
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
|
|
(dollars in
millions)
|
|
|
Selling, general and
administrative
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1
|
|
|
|
Other operating
income, net
|
—
|
|
|
(6)
|
|
|
—
|
|
|
(15)
|
|
|
|
Operating
income
|
$
|
—
|
|
|
$
|
(6)
|
|
|
$
|
—
|
|
|
$
|
(14)
|
|
|
(d)
|
For restructuring and
integration charges, COVID-19 impacts, other items and amortization
expense, income tax impacts, where recorded, were primarily
calculated using combined statutory income tax rates of 25.5% for
both 2020 and 2019. For the gain associated with an insurance
claim for hurricane related losses in 2019, there was no net income
tax expense as the company was able to utilize net operating loss
carryforwards for which a valuation allowance had previously been
established. For the gain in 2019 associated with the
decrease in the fair value of the contingent consideration accrual
associated with a previous acquisition, there was no net income tax
expense as the gain is non-taxable.
|
|
|
|
3)
|
Discontinued
operations, net of taxes, for the three and six months ended
June 30, 2019 includes discrete tax benefits of $20 million
associated with the favorable resolution of certain tax
contingencies related to Nichols Institute Diagnostics, a test kit
manufacturing subsidiary whose operations were discontinued in
2006.
|
|
|
|
4)
|
For the
three months ended June 30, 2020, the company did not
repurchase any shares of its common stock. For the six months
ended June 30, 2020, the company repurchased 0.7 million
shares of its common stock for $75 million. As of
June 30, 2020, $1.2 billion remained available under the
company's share repurchase authorizations; however the company has
temporarily suspended additional share repurchases under the
existing authorization through the end of 2020.
|
|
|
|
5)
|
For the six months
ended June 30, 2020, net cash provided by operating activities
includes $65 million that the company received from the initial
tranche of funds that were appropriated to healthcare providers
under the CARES Act.
|
|
|
|
6)
|
The outlook for
adjusted diluted EPS represents management's estimates for the full
year 2020 before the impact of special items. Further impacts to
earnings related to special items may occur throughout 2020.
Both reported and adjusted diluted EPS exclude any proceeds that we
may receive from the secondary tranche of funds distributed to
healthcare providers under the CARES Act. Additionally, the
amount of ETB is dependent upon employee stock option exercises and
the company's stock price, which are difficult to predict. The
following table reconciles our 2020 outlook for adjusted diluted
EPS to the corresponding amounts determined under GAAP:
|
|
|
|
Low
|
|
High
|
|
|
Diluted
EPS
|
$
|
5.66
|
|
|
$
|
7.66
|
|
|
|
Restructuring and
integration charges (a)
|
0.50
|
|
|
0.50
|
|
|
|
COVID-19
impact
|
(0.10)
|
|
|
(0.10)
|
|
|
|
Amortization expense
(b)
|
0.65
|
|
|
0.65
|
|
|
|
ETB
|
(0.11)
|
|
|
(0.11)
|
|
|
|
Adjusted diluted
EPS
|
$
|
6.60
|
|
|
$
|
8.60
|
|
|
(a)
|
Represents estimated
full year pre-tax charges of $90 million primarily associated with
systems conversions and integration costs incurred in connection
with further restructuring and integrating our business.
Income tax benefits were calculated using a combined statutory
income tax rate of 25.5%.
|
|
|
|
|
(b)
|
Represents the
estimated impact of amortization expense for 2020 on the
calculation of adjusted diluted EPS. Amortization expense used in
the calculation is as follows (dollars in millions):
|
|
|
Amortization of
intangible assets
|
$
|
107
|
|
|
|
Amortization expense
included in equity in earnings of equity method investees, net of
taxes
|
11
|
|
|
|
Total pre-tax
amortization expense
|
$
|
118
|
|
|
|
|
|
|
|
Total amortization
expense, net of an estimated tax benefit using a combined statutory
income tax rate of 25.5%
|
$
|
88
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-reports-second-quarter-2020-financial-results-301098272.html
SOURCE Quest Diagnostics